Legal & General Group PLC Lineage Cell Therapeutics, Inc. Transaction History
Legal & General Group PLC
- $357 Billion
- Q1 2025
A detailed history of Legal & General Group PLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 15,644 shares of LCTX stock, worth $10,794. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,644
Previous 15,644
-0.0%
Holding current value
$10,794
Previous $7,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding LCTX
# of Institutions
138Shares Held
108MCall Options Held
8KPut Options Held
3K-
Broadwood Capital Inc New York, NY49.6MShares$34.2 Million1.86% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$6.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$6.15 Million0.0% of portfolio
-
Defender Capital, Llc.6.31MShares$4.35 Million1.19% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$3.89 Million3.45% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $117M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...